why choose us

First received: February 08, 2023

Clinical Trial: A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Thyroid Cancer

Study Type: OBSERVATIONAL


Official Title: Outcomes of Patients With Thyroid Carcinoma Treated With Redifferentiating Agents as Part of Routine Clinical Care: A Prospective Data Collection Study

Brief Summary: The purpose of this study to learn more about the use of redifferentiating medications as a standard treatment for radioactive iodine/RAI-refractory thyroid cancer.This study is a registry study.

Read more